Interventional, open-label study of 18 mg Selincro(R) as needed use, in the treatment of patients with alcohol dependence in primary care
Phase of Trial: Phase IV
Latest Information Update: 30 Mar 2017
At a glance
- Drugs Nalmefene (Primary)
- Indications Alcohol withdrawal
- Focus Therapeutic Use
- Sponsors Lundbeck A/S
- 29 Mar 2016 Status changed from completed to discontinued due to enrolment challenges as reported by ClinicalTrials.gov record.
- 16 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Oct 2015 Planned End Date changed from 1 Apr 2016 to 1 Jan 2016 as reported by ClinicalTrials.gov.